Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha.
Durlik
M
M
Transplantation Institute, Warsaw Medical School, Poland.
Gaciong
Z
Z
Rancewicz
Z
Z
Rowińska
D
D
Wyzgał
J
J
Kozłowska
B
B
Gradowska
L
L
Lao
M
M
Nowaczyk
M
M
Korczak-Kowalska
G
G
D000328:Adult; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006684:HLA-DR Antigens / Q000096:biosynthesis / Q000097:blood; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006526:Hepatitis C / Q000150:complications / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000096:biosynthesis; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
D006684:HLA-DR Antigens; D007370:Interferon Type I; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D003404:Creatinine